Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Inflammation
Published in: Inflammation 6/2000

01-12-2000

Effect of the COX-2 Selective Inhibitor L-745,337 on Inflammation and Organ Prostaglandin E2 (PGE2) Levels in Adjuvant Arthritic Rats

Authors: Àngels Turull, Josep Queralt

Published in: Inflammation | Issue 6/2000

Login to get access
Metadata
Title
Effect of the COX-2 Selective Inhibitor L-745,337 on Inflammation and Organ Prostaglandin E2 (PGE2) Levels in Adjuvant Arthritic Rats
Authors
Àngels Turull
Josep Queralt
Publication date
01-12-2000
Publisher
Kluwer Academic Publishers-Plenum Publishers
Published in
Inflammation / Issue 6/2000
Print ISSN: 0360-3997
Electronic ISSN: 1573-2576
DOI
https://doi.org/10.1023/A:1007025423232

Other articles of this Issue 6/2000

Inflammation 6/2000 Go to the issue

OriginalPaper

Lung Compartmentalization of Inflammatory Cells in Sepsis

OriginalPaper

Regulation of Chemokine mRNA Expression in a Rat Model of Vanadium-Induced Pulmonary Inflammation

OriginalPaper

Phagocytosis and Chemiluminescence Response of Granulocytes to Monodisperse Latex Particles of Varying Sizes and Surface Coats

OriginalPaper

Receptor Mediated Endocytosis by Mesangial Cells Modulates Transmigration of Macrophages

OriginalPaper

Role of P-Selectin in the Migration of Neutrophils to Chemoattractant-Induced Cutaneous Inflammation in Mice

OriginalPaper

Opinion:: Resolution of Lyme Arthritis, Acute or Prolonged: A New Look
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits